{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:35:04Z","timestamp":1794407704839,"version":"4.9.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["668031"],"award-info":[{"award-number":["668031"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF15OC0016692"],"award-info":[{"award-number":["NNF15OC0016692"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF15OC0016692"],"award-info":[{"award-number":["NNF15OC0016692"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-60755-9","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T13:25:39Z","timestamp":1751376339000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The postbiotic ReFerm\u00ae versus standard nutritional support in advanced alcohol-related liver disease (GALA-POSTBIO): a randomized controlled phase 2 trial"],"prefix":"10.1038","volume":"16","author":[{"given":"Johanne K.","family":"Hansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Israelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Nishijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1491-9179","authenticated-orcid":false,"given":"Sara E.","family":"Stinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5031-2294","authenticated-orcid":false,"given":"Stine","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla D.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2879-7560","authenticated-orcid":false,"given":"Maximilian Joseph","family":"Brol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2195-3666","authenticated-orcid":false,"given":"Robert","family":"Schierwagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank Erhard","family":"Uschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7117-3756","authenticated-orcid":false,"given":"Karolina","family":"Sulek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida F.","family":"Villesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrine P.","family":"Lindvig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0411-0373","authenticated-orcid":false,"given":"Katrine H.","family":"Thorhauge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaj","family":"Torp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane M.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1485-415X","authenticated-orcid":false,"given":"Marisa Isabell","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gitte H.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9466-2333","authenticated-orcid":false,"given":"S\u00f6nke","family":"Detlefsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana J.","family":"Leeming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6433-6975","authenticated-orcid":false,"given":"Evelina","family":"Stankevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2583-4912","authenticated-orcid":false,"given":"Tommi","family":"Suvitaival","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andressa","family":"Zawadzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2841-872X","authenticated-orcid":false,"given":"Michael","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7885-715X","authenticated-orcid":false,"given":"Lars Juhl","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7028-3881","authenticated-orcid":false,"given":"Jonel","family":"Trebicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Israelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Legido-Quigley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peer","family":"Bork","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0886-9101","authenticated-orcid":false,"given":"Manimozhiyan","family":"Arumugam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8748-3831","authenticated-orcid":false,"given":"Torben","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1854-1924","authenticated-orcid":false,"given":"Maja","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9598-4932","authenticated-orcid":false,"given":"Aleksander","family":"Krag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"60755_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","volume":"399","author":"TH Karlsen","year":"2022","unstructured":"Karlsen, T. H. et al. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 399, 61\u2013116 (2022).","journal-title":"Lancet"},{"key":"60755_CR2","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1056\/NEJMra1600266","volume":"375","author":"SV Lynch","year":"2016","unstructured":"Lynch, S. V. & Pedersen, O. The human intestinal microbiome in health and disease. N. Engl. J. Med. 375, 2369\u20132379 (2016).","journal-title":"N. Engl. J. Med."},{"key":"60755_CR3","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jhep.2013.12.019","volume":"60","author":"JS Bajaj","year":"2014","unstructured":"Bajaj, J. S. et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J. Hepatol. 60, 940\u2013947 (2014).","journal-title":"J. Hepatol."},{"key":"60755_CR4","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1002\/j.2040-4603.2013.tb00529.x","volume":"3","author":"JE Puche","year":"2013","unstructured":"Puche, J. E., Saiman, Y. & Friedman, S. L. Hepatic stellate cells and liver fibrosis. Compr. Physiol. 3, 1473\u20131492 (2013).","journal-title":"Compr. Physiol."},{"key":"60755_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/BF01324802","volume":"430","author":"ML Hautekeete","year":"1997","unstructured":"Hautekeete, M. L. & Geerts, A. The hepatic stellate (Ito) cell: its role in human liver disease. Virchows Arch. 430, 195\u2013207 (1997).","journal-title":"Virchows Arch."},{"key":"60755_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.153798","volume":"231","author":"MD S\u00f8rensen","year":"2022","unstructured":"S\u00f8rensen, M. D. et al. Stage-dependent expression of fibrogenic markers in alcohol-related liver disease. Pathol. Res. Pract. 231, 153798 (2022).","journal-title":"Pathol. Res. Pract."},{"key":"60755_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/BF00194608","volume":"424","author":"H Enzan","year":"1994","unstructured":"Enzan, H. et al. Immunohistochemical identification of Ito cells and their myofibroblastic transformation in adult human liver. Virchows Arch. 424, 249\u2013256 (1994).","journal-title":"Virchows Arch."},{"key":"60755_CR8","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1136\/gutjnl-2020-320786","volume":"70","author":"TH Tranah","year":"2021","unstructured":"Tranah, T. H., Edwards, L. A., Schnabl, B. & Shawcross, D. L. Targeting the gut-liver-immune axis to treat cirrhosis. Gut 70, 982\u2013994 (2021).","journal-title":"Gut"},{"key":"60755_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41575-020-00376-3","volume":"18","author":"J Trebicka","year":"2021","unstructured":"Trebicka, J., Bork, P., Krag, A. & Arumugam, M. Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure. Nat. Rev. Gastroenterol. Hepatol. 18, 167\u2013180 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"60755_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.913842","volume":"9","author":"JH Jung","year":"2022","unstructured":"Jung, J. H., Kim, S. E., Suk, K. T. & Kim, D. J. Gut microbiota-modulating agents in alcoholic liver disease: Links between host metabolism and gut microbiota. Front. Med.9, 913842 (2022).","journal-title":"Front. Med."},{"key":"60755_CR11","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","volume":"72","author":"A Albillos","year":"2020","unstructured":"Albillos, A., de Gottardi, A. & Rescigno, M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J. Hepatol. 72, 558\u2013577 (2020).","journal-title":"J. Hepatol."},{"key":"60755_CR12","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/0016-5085(95)90027-6","volume":"108","author":"Y Adachi","year":"1995","unstructured":"Adachi, Y., Moore, L. E., Bradford, B. U., Gao, W. & Thurman, R. G. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 108, 218\u2013224 (1995).","journal-title":"Gastroenterology"},{"key":"60755_CR13","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41575-021-00440-6","volume":"18","author":"S Salminen","year":"2021","unstructured":"Salminen, S. et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat. Rev. Gastroenterol. Hepatol. 18, 649\u2013667 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"60755_CR14","doi-asserted-by":"crossref","unstructured":"Hsu, C. L. & Schnabl, B. The gut-liver axis and gut microbiota in health and liver disease. Nat. Rev. Microbiol. 21, 719\u2013733 (2023).","DOI":"10.1038\/s41579-023-00904-3"},{"key":"60755_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.1004084","volume":"9","author":"O Bednarska","year":"2022","unstructured":"Bednarska, O. et al. A postbiotic fermented oat gruel may have a beneficial effect on the colonic mucosal barrier in patients with irritable bowel syndrome. Front. Nutr. 9, 1004084 (2022).","journal-title":"Front. Nutr."},{"key":"60755_CR16","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1097\/01.MIB.0000437046.26036.db","volume":"19","author":"A Krag","year":"2013","unstructured":"Krag, A. et al. Profermin is efficacious in patients with active ulcerative colitis\u2013a randomized controlled trial. Inflamm. Bowel Dis. 19, 2584\u20132592 (2013).","journal-title":"Inflamm. Bowel Dis."},{"key":"60755_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100987","volume":"6","author":"JW Jaeger","year":"2024","unstructured":"Jaeger, J. W. et al. Microbiota modulation by dietary oat beta-glucan prevents steatotic liver disease progression. JHEP Rep. 6, 100987 (2024).","journal-title":"JHEP Rep."},{"key":"60755_CR18","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jhep.2022.11.013","volume":"78","author":"A Louvet","year":"2023","unstructured":"Louvet, A. et al. Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort. J. Hepatol. 78, 501\u2013512 (2023).","journal-title":"J. Hepatol."},{"key":"60755_CR19","doi-asserted-by":"crossref","unstructured":"Thorhauge, K. H. et al. Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease. J. Hepatol. 81, 23\u201332 (2024).","DOI":"10.1016\/j.jhep.2024.02.019"},{"key":"60755_CR20","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1053\/j.gastro.2020.05.007","volume":"159","author":"D Kim","year":"2020","unstructured":"Kim, D. et al. Decline in annual mortality of hepatitis C virus-related hepatocellular carcinoma in the United States, from 2009 to 2018. Gastroenterology 159, 1558\u20131560 e2 (2020).","journal-title":"Gastroenterology"},{"key":"60755_CR21","doi-asserted-by":"crossref","unstructured":"Israelsen, M. et al. Impact of acute alcohol consumption on circulating microbiome in asymptomatic alcohol-related liver disease. Gut (2023).","DOI":"10.1136\/gutjnl-2023-330360"},{"key":"60755_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nature13568","volume":"513","author":"N Qin","year":"2014","unstructured":"Qin, N. et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 513, 59\u201364 (2014).","journal-title":"Nature"},{"key":"60755_CR23","doi-asserted-by":"publisher","first-page":"E4485","DOI":"10.1073\/pnas.1415174111","volume":"111","author":"S Leclercq","year":"2014","unstructured":"Leclercq, S. et al. Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proc. Natl. Acad. Sci. USA 111, E4485\u2013E4493 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60755_CR24","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/S0168-8278(00)80242-1","volume":"32","author":"A Parlesak","year":"2000","unstructured":"Parlesak, A., Sch\u00e4fer, C., Sch\u00fctz, T., Bode, J. C. & Bode, C. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J. Hepatol. 32, 742\u2013747 (2000).","journal-title":"J. Hepatol."},{"key":"60755_CR25","doi-asserted-by":"crossref","unstructured":"Schoultz, I. & Keita, \u00c5. V. The intestinal barrier and current techniques for the assessment of gut permeability. Cells 9, 1909 (2020).","DOI":"10.3390\/cells9081909"},{"key":"60755_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12986-016-0089-7","volume":"13","author":"E Lau","year":"2016","unstructured":"Lau, E. et al. The role of I-FABP as a biomarker of intestinal barrier dysfunction driven by gut microbiota changes in obesity. Nutr. Metab.13, 31 (2016).","journal-title":"Nutr. Metab."},{"key":"60755_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-01709-0","volume":"7","author":"I Graupera","year":"2017","unstructured":"Graupera, I. et al. Adipocyte fatty-acid binding protein is overexpressed in cirrhosis and correlates with clinical outcomes. Sci. Rep. 7, 1829 (2017).","journal-title":"Sci. Rep."},{"key":"60755_CR28","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jhep.2021.09.010","volume":"76","author":"VC Patel","year":"2022","unstructured":"Patel, V. C. et al. Rifaximin-alpha reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial. J. Hepatol. 76, 332\u2013342 (2022).","journal-title":"J. Hepatol."},{"key":"60755_CR29","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S2468-1253(23)00010-9","volume":"8","author":"M Israelsen","year":"2023","unstructured":"Israelsen, M. et al. Rifaximin-\u03b1 for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Gastroenterol. Hepatol. 8, 523\u2013532 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"60755_CR30","doi-asserted-by":"publisher","first-page":"9448","DOI":"10.1073\/pnas.1201840109","volume":"109","author":"T Kisseleva","year":"2012","unstructured":"Kisseleva, T. et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc. Natl. Acad. Sci. USA 109, 9448\u20139453 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60755_CR31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.dld.2004.11.009","volume":"37","author":"G Carpino","year":"2005","unstructured":"Carpino, G. et al. Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation. Dig. Liver Dis. 37, 349\u2013356 (2005).","journal-title":"Dig. Liver Dis."},{"key":"60755_CR32","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1111\/j.1478-3231.2012.02774.x","volume":"32","author":"MY Kim","year":"2012","unstructured":"Kim, M. Y. et al. Beneficial effects of candesartan, an angiotensin-blocking agent, on compensated alcoholic liver fibrosis\u2014a randomized open-label controlled study. Liver Int. 32, 977\u2013987 (2012).","journal-title":"Liver Int."},{"key":"60755_CR33","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/hep.32204","volume":"75","author":"AJ Sanyal","year":"2022","unstructured":"Sanyal, A. J. et al. Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. Hepatology 75, 1235\u20131246 (2022).","journal-title":"Hepatology"},{"key":"60755_CR34","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1111\/liv.15595","volume":"43","author":"S Johansen","year":"2023","unstructured":"Johansen, S. et al. Validation of scores of PRO-C3 to predict liver-related events in alcohol-related liver disease. Liver Int. 43, 1486\u20131496 (2023).","journal-title":"Liver Int."},{"key":"60755_CR35","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1053\/j.gastro.2023.06.030","volume":"165","author":"G Semmler","year":"2023","unstructured":"Semmler, G. et al. Dynamics in liver stiffness measurements predict outcomes in advanced chronic liver disease. Gastroenterology 165, 1041\u20131052 (2023).","journal-title":"Gastroenterology"},{"key":"60755_CR36","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.adf6696","volume":"16","author":"VQ Trinh","year":"2023","unstructured":"Trinh, V. Q. et al. Hepatic stellate cells maintain liver homeostasis through paracrine neurotrophin-3 signaling that induces hepatocyte proliferation. Sci. Signal. 16, eadf6696 (2023).","journal-title":"Sci. Signal."},{"key":"60755_CR37","doi-asserted-by":"publisher","first-page":"5963","DOI":"10.7150\/ijbs.72982","volume":"18","author":"Z Yang","year":"2022","unstructured":"Yang, Z. et al. Neurotrophin3 promotes hepatocellular carcinoma apoptosis through the JNK and P38 MAPK pathways. Int. J. Biol. Sci. 18, 5963\u20135977 (2022).","journal-title":"Int. J. Biol. Sci."},{"key":"60755_CR38","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41421-021-00326-6","volume":"7","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. SIRT2-mediated deacetylation and deubiquitination of C\/EBP\u03b2 prevents ethanol-induced liver injury. Cell Discov. 7, 93 (2021).","journal-title":"Cell Discov."},{"key":"60755_CR39","doi-asserted-by":"publisher","first-page":"e15398","DOI":"10.1371\/journal.pone.0015398","volume":"5","author":"LA Edwards","year":"2010","unstructured":"Edwards, L. A. et al. Delineation of the innate and adaptive T-cell immune outcome in the human host in response to Campylobacter jejuni infection. PLoS ONE 5, e15398 (2010).","journal-title":"PLoS ONE"},{"key":"60755_CR40","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jhep.2021.09.010","volume":"76","author":"VC Patel","year":"2022","unstructured":"Patel, V. C. et al. Rifaximin-\u03b1 reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial. J. Hepatol. 76, 332\u2013342 (2022).","journal-title":"J. Hepatol."},{"key":"60755_CR41","doi-asserted-by":"publisher","first-page":"16551","DOI":"10.1073\/pnas.1904885116","volume":"116","author":"J Fischer","year":"2019","unstructured":"Fischer, J. et al. Leptin signaling impairs macrophage defenses against Salmonella Typhimurium. Proc. Natl. Acad. Sci. USA 116, 16551\u201316560 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60755_CR42","doi-asserted-by":"crossref","unstructured":"Macnaughtan, J. et al. A double-blind, randomized placebo-controlled trial of probiotic Lactobacillus casei Shirota in stable cirrhotic patients. Nutrients 12, 1651 (2020).","DOI":"10.3390\/nu12061651"},{"key":"60755_CR43","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1111\/liv.12798","volume":"35","author":"AD Fialla","year":"2015","unstructured":"Fialla, A. D., Israelsen, M., Hamberg, O., Krag, A. & Gluud, L. L. Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic review and meta-analysis. Liver Int. 35, 2072\u20132078 (2015).","journal-title":"Liver Int."},{"key":"60755_CR44","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1016\/j.clnu.2020.09.001","volume":"39","author":"SC Bischoff","year":"2020","unstructured":"Bischoff, S. C. et al. ESPEN practical guideline: clinical nutrition in liver disease. Clin. Nutr. 39, 3533\u20133562 (2020).","journal-title":"Clin. Nutr."},{"key":"60755_CR45","doi-asserted-by":"publisher","first-page":"189","DOI":"10.4132\/jptm.2023.05.24","volume":"57","author":"MJ Lee","year":"2023","unstructured":"Lee, M. J. A review of liver fibrosis and cirrhosis regression. J. Pathol. Transl. Med. 57, 189\u2013195 (2023).","journal-title":"J. Pathol. Transl. Med."},{"key":"60755_CR46","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78, 1966\u20131986 (2023).","journal-title":"Hepatology"},{"key":"60755_CR47","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S2468-1253(23)00443-0","volume":"9","author":"M Israelsen","year":"2024","unstructured":"Israelsen, M. et al. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Lancet Gastroenterol. Hepatol. 9, 218\u2013228 (2024).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"60755_CR48","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.3748\/wjg.v18.i15.1773","volume":"18","author":"A Krag","year":"2012","unstructured":"Krag, A., Israelsen, H., von Ryberg, B., Andersen, K. K. & Bendtsen, F. Safety and efficacy of Profermin\u00ae to induce remission in ulcerative colitis. World J. Gastroenterol. 18, 1773\u20131780 (2012).","journal-title":"World J. Gastroenterol."},{"key":"60755_CR49","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1443-9573.2006.00265.x","volume":"7","author":"DA Drossman","year":"2006","unstructured":"Drossman, D. A. Rome III: the new criteria. Chin. J. Dig. Dis. 7, 181\u2013185 (2006).","journal-title":"Chin. J. Dig. Dis."},{"key":"60755_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris, P. A. et al. The REDCap consortium: building an international community of software platform partners. J. Biomed. Inf. 95, 103208 (2019).","journal-title":"J. Biomed. Inf."},{"key":"60755_CR51","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313\u20131321 (2005).","journal-title":"Hepatology"},{"key":"60755_CR52","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1055\/a-0641-0076","volume":"38","author":"CF Dietrich","year":"2017","unstructured":"Dietrich, C. F. et al. EFSUMB guidelines and recommendations on the clinical use of liver ultrasound elastography, update 2017 (long version). Ultraschall Med. 38, e48 (2017).","journal-title":"Ultraschall Med."},{"key":"60755_CR53","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"EASL","year":"2021","unstructured":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u20142021 update. J. Hepatol. 75, 659\u2013689 (2021).","journal-title":"J. Hepatol."},{"key":"60755_CR54","doi-asserted-by":"publisher","first-page":"5555","DOI":"10.1007\/s00216-017-0493-5","volume":"409","author":"C Lotti","year":"2017","unstructured":"Lotti, C. et al. Development of a fast and cost-effective gas chromatography-mass spectrometry method for the quantification of short-chain and medium-chain fatty acids in human biofluids. Anal. Bioanal. Chem. 409, 5555\u20135567 (2017).","journal-title":"Anal. Bioanal. Chem."},{"key":"60755_CR55","doi-asserted-by":"publisher","first-page":"G182","DOI":"10.1152\/ajpgi.00361.2018","volume":"317","author":"MJ Brol","year":"2019","unstructured":"Brol, M. J. et al. Combination of CCl(4) with alcoholic and metabolic injuries mimics human liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 317, G182\u2013g94 (2019).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"60755_CR56","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nprot.2008.73","volume":"3","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3, 1101\u20131108 (2008).","journal-title":"Nat. Protoc."},{"key":"60755_CR57","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome, P. N. et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N. Engl. J. Med. 384, 1113\u20131124 (2021).","journal-title":"N. Engl. J. Med."},{"key":"60755_CR58","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1001\/jama.2022.21506","volume":"328","author":"MJ Holmberg","year":"2022","unstructured":"Holmberg, M. J. & Andersen, L. W. Adjustment for baseline characteristics in randomized clinical trials. JAMA 328, 2155\u20132156 (2022).","journal-title":"JAMA"},{"key":"60755_CR59","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41586-021-04233-4","volume":"601","author":"LP Coelho","year":"2022","unstructured":"Coelho, L. P. et al. Towards the biogeography of prokaryotic genes. Nature 601, 252\u2013256 (2022).","journal-title":"Nature"},{"key":"60755_CR60","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754\u201360 (2009).","journal-title":"Bioinformatics"},{"key":"60755_CR61","doi-asserted-by":"publisher","first-page":"5825","DOI":"10.1093\/molbev\/msab293","volume":"38","author":"CP Cantalapiedra","year":"2021","unstructured":"Cantalapiedra, C. P., Hern\u00e1ndez-Plaza, A., Letunic, I., Bork, P. & Huerta-Cepas, J. eggNOG-mapper v2: Functional Annotation, Orthology Assignments, and Domain Prediction at the Metagenomic Scale. Mol. Biol. Evol. 38, 5825\u20135829 (2021).","journal-title":"Mol. Biol. Evol."},{"key":"60755_CR62","doi-asserted-by":"publisher","first-page":"D309","DOI":"10.1093\/nar\/gky1085","volume":"47","author":"J Huerta-Cepas","year":"2019","unstructured":"Huerta-Cepas, J. et al. eggNOG 5.0: a hierarchical, functionally and phylogenetically annotated orthology resource based on 5090 organisms and 2502 viruses. Nucleic Acids Res. 47, D309\u2013D314 (2019).","journal-title":"Nucleic Acids Res."},{"key":"60755_CR63","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51, D587\u2013D592 (2023).","journal-title":"Nucleic Acids Res."},{"key":"60755_CR64","first-page":"100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu, T. et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation 2, 100141 (2021).","journal-title":"Innovation"},{"key":"60755_CR65","doi-asserted-by":"crossref","unstructured":"Ahonen, L. et al. Targeted Clinical Metabolite Profiling Platform for the Stratification of Diabetic Patients. Metabolites 9, 184 (2019).","DOI":"10.3390\/metabo9090184"},{"key":"60755_CR66","doi-asserted-by":"crossref","unstructured":"Zawadzki, A. et al. High-Throughput UHPLC-MS to Screen Metabolites in Feces for Gut Metabolic Health. Metabolites 12, 211 (2022).","DOI":"10.3390\/metabo12030211"},{"key":"60755_CR67","doi-asserted-by":"publisher","first-page":"100325","DOI":"10.1016\/j.jhepr.2021.100325","volume":"3","author":"M Israelsen","year":"2021","unstructured":"Israelsen, M. et al. Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication. JHEP Rep. 3, 100325 (2021).","journal-title":"JHEP Rep."},{"key":"60755_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-11-395","volume":"11","author":"T Pluskal","year":"2010","unstructured":"Pluskal, T., Castillo, S., Villar-Briones, A. & Oresic, M. MZmine 2: modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinforma. 11, 395 (2010).","journal-title":"BMC Bioinforma."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60755-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60755-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60755-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:02:17Z","timestamp":1751382137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60755-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["60755"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-60755-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"4 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.K.H. has received a speaker\u2019s fee from Norgine A\/S. M.I.\u2019s father and co-author, H.I., is full-time employed and a stockholder at Nordic Rebalance that produces ReFerm\u00ae. M.I. is not employed and is not a stockholder in the company. S.E.S. was funded by the NNF Copenhagen Bioscience PhD Program (grant no. NNF18CC0033668). C.D.H.: Received speaker\u2019s fee from Novo Nordisk. K.S. is funded by the Novo Nordisk Foundation Excellence Emerging Investigator Grant\u2014Endocrinology and Metabolism 2022 (grant no. NNF 0074491). Involved in various projects with funding from or directly with Novo Nordisk A\/S, all outside the submitted work. K.P.L. has received a speaker\u2019s fee from Siemens and Novo Nordisk and is a board member and co-founder of Evido. D.J.L. and M.Ka. are full-time employees and stockholders at Nordic Bioscience. A.Z. is a full-time employee of Nordic Bioscience. L.J.J. is funded by grants from the Novo Nordisk Foundation (grant numbers NNF14CC0001 and NNF21OC0068988) and has a paid position on the scientific advisory board of ZS Associates unrelated to the submitted work. J.T. has received speaking and\/or consulting fees from Versantis, Gore, Boehringer Ingelheim, Alexion, Falk, Grifols, CSL Behring, and Genfit. M.Ka. is a full-time employee and stockholder at Nordic Bioscience. H.I. is a full-time employee and stockholder at Nordic Rebalance that produces ReFerm\u00ae. T.H. Stockholder at Novo Nordisk. Research support; Novo Nordisk, GSK. M.T. is funded by a grant from the Novo Nordisk Foundation (DECIDE, grant number NNF20OC0059393). Received speaker\u2019s fee from Novo Nordisk, Echosens, Madrigal, and Takeda. Advisory fee from Boehringer Ingelheim, Astra Zeneca, Novo Nordisk, and GSK. Co-founder of Evido. Received an investigator-initiated grant from GSK. A.K. has served as a speaker for Novo Nordisk, Norgine, Siemens, and Nordic Bioscience and participated in advisory boards for Norgine, Siemens, Resalis Therapeutics, Boehringer Ingelheim, and Novo Nordisk, all outside the submitted work. Research support: Norgine, Siemens, Nordic Bioscience, Astra, Echosens. Board member and co-founder of Evido. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5969"}}